Stay updated on Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial page.

Latest updates to the Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision updated to v3.4.2, replacing the prior v3.4.1.SummaryDifference0.1%

- Check20 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1.SummaryDifference0.1%

- Check27 days agoChange DetectedA glossary feature was added to the page, and there are minor text/capitalization changes plus a new version label (Revision: v3.4.0). The core study content and user actions remain unchanged.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed.SummaryDifference0.1%

- Check63 days agoChange DetectedLocations section reorganized under a single Locations heading listing Florida and North Carolina; the HHS Vulnerability Disclosure link was removed and the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.3%

- Check91 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2; no study content changes observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial page.